Patients with elevated SERPINH1 in both tumor and NATs (T2-NAT2) exhibited the highest risk of recurrence, with a 5-year DFS rate reaching 78.95% (Figure 6B and J). The gene discussed is SERPINH1; the disease is neoplasm.